当前理念：间充质干细胞在膝骨关节炎治疗中的作用。
Current concepts: the role of mesenchymal stem cells in the management of knee osteoarthritis.
机构信息
University Health Network Arthritis Program, University of Toronto, Toronto, Ontario, Canada.
Rush University Medical Centre, Chicago, Illinois.
出版信息
Sports Health. 2015 Jan;7(1):38-44. doi: 10.1177/1941738114529727.
CONTEXT
The number of adults with osteoarthritis in the United States is expected to nearly double from 21.4 million in 2005 to 41.1 million by 2030. As a result, medical costs and associated comorbidity will exponentially increase in the coming decades. In the past decade, mesenchymal stem cells (MSCs) have emerged as a novel treatment for degenerative joint disease.
EVIDENCE ACQUISITION
PubMed (from 1990 to 2013) was searched to identify relevant studies. Reference lists of included studies were also reviewed.
STUDY DESIGN
Clinical review.
LEVEL OF EVIDENCE
Level 3.
RESULTS
We identified 9 animal and 7 human studies investigating the use of MSCs in the treatment of osteoarthritis, with varying levels of support for this therapy.
CONCLUSION
While MSCs have shown potential for improving function and decreasing inflammation in animal studies, translation to patients is still in question. There is a great deal of heterogeneity in treatment methods. Standardizing the manufacturing and characterization of MSCs will allow for better comparisons.
背景
预计到 2030 年，美国患骨关节炎的成年人数量将从 2005 年的 2140 万增加近一倍，达到 4110 万。因此，未来几十年医疗费用和相关合并症将呈指数级增长。在过去十年中，间充质干细胞（MSCs）已成为退行性关节疾病的一种新的治疗方法。
证据获取
从 1990 年至 2013 年，对 PubMed 进行了检索，以确定相关研究。还对纳入研究的参考文献进行了回顾。
研究设计
临床综述。
证据水平
3 级。
结果
我们确定了 9 项动物研究和 7 项人类研究，调查了 MSCs 在治疗骨关节炎中的应用，该疗法得到了不同程度的支持。
结论
虽然 MSCs 在动物研究中显示出改善功能和减少炎症的潜力，但在患者中的转化仍存在疑问。治疗方法存在很大的异质性。标准化 MSCs 的制造和表征将允许更好的比较。
Zotero 插件